Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Affimed N.V. - Common Stock (NQ:AFMD)

0.7099 -0.0133 (-1.84%)
Streaming Delayed Price Updated: 3:59 PM EDT, Apr 1, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Affimed N.V. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
The Daily Biotech Pulse: Spero Spikes On Pfizer Investment, FDA Nod For Jazz, Orchard Signs Licensing Deal, Acumen Pharma Debuts
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 30) Ambrx Biopharma Inc. (NYSE... 
Via Benzinga
Exposures Product Safety
Earnings Scheduled For July 1, 2021
Companies Reporting Before The Bell • Simply Good Foods (NASDAQ:SMPL) is projected to report quarterly earnings at $0.29 per share on revenue of $244.29 million.... 
Via Benzinga
Affimed Earnings Preview
Affimed (NASDAQ:AFMD) announces its next round of earnings this Thursday, July 01. Here is Benzinga's look at Affimed's Q1 earnings report. Net Income, Earnings, And Earnings Per... 
Via Benzinga
Stocks That Hit 52-Week Highs On Friday
On Friday morning, 152 companies hit new 52-week highs. Things to Consider: The largest company by market cap to hit a new 52-week high was ASML Holding (NASDAQ:... 
Via Benzinga
Preview: Affimed's Earnings
On Thursday, April 15, Affimed (NASDAQ:AFMD) will release its latest earnings report. Check out Benzinga's preview to understand the implications. What Are Earnings, Net... 
Via Benzinga
Stocks That Hit 52-Week Highs On Friday
During the morning session on Friday, 178 stocks hit new 52-week highs. Noteworthy Points: Microsoft (NASDAQ:MSFT) was the largest firm on a market cap basis to set... 
Via Benzinga
The Week Ahead In Biotech: Mediwound, Provention FDA Decisions, IPOs, Pending Clinical Readouts In Focus
Biotech stocks reversed course and closed the week ended June 25 higher, thanks to the positive broader market sentiment. Eli Lilly and Company (NYSE: LLY) stood out among big... 
Via Benzinga
Exposures Product Safety
Affimed's AFM13 In Combination With NK Cells Show Improved Tumor Recognition, Killing In Preclinical Studies
Affimed NV (NASDAQ: AFMD) has announced the publication of in vitro and in vivo research of its lead innate cell engager (ICE), AFM13 (CD16A/CD30), combined... 
Via Benzinga
Could Affimed Be a Millionaire-Maker Stock?
This biotech stock has already produced some big returns this year. 
Via The Motley Fool
Why Affimed N.V. Stock Dropped Today
The company's latest quarterly update was less than impressive. 
Via The Motley Fool
The Daily Biotech Pulse: Lilly, Novartis Trail Q1 Estimates, Exec Departure At Applied Genetics, Patent Award For Scholar Rock, Aldeyra Data Readout
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 26) 10x Genomics, Inc. (NASDAQ... 
Via Benzinga
Topics Intellectual Property
Exposures Intellectual Property
Earnings Scheduled For April 15, 2021
Companies Reporting Before The Bell • Charles Schwab (NYSE:SCHW) is projected to report quarterly earnings at $0.82 per share on revenue of $4.58 billion. •... 
Via Benzinga
The Daily Biotech Pulse: Merck Shelves 2 COVID-19 Studies, Bristol-Myers Squibb Gets European Regulatory Nod, InspireMD's Reverse Split
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 14) 10x Genomics, Inc. (NASDAQ... 
Via Benzinga
Exposures COVID-19
The Week Ahead In Biotech (April 11-17): Avenue Therapeutics FDA Decision and Conference Presentations In The Spotlight
Contrary to the strength in the broader market, biotech stocks ended the week ending April 9 lower. The weakness partly reflected a preference for risky bets at the expense of... 
Via Benzinga
Exposures Product Safety
The Daily Biotech Pulse: Leadership Transition At Amarin, Vaccine Setback For J&J, FDA Nod For Label Expansion of Roche's Asthma Drug
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 12) 180 Life Sciences Corp. (... 
Via Benzinga
Exposures Product Safety
Here's Why Shares of Affimed Skyrocketed Today
A 100% response rate is impressive, albeit in just four patients. 
Via The Motley Fool
51 Biggest Movers From Friday
Gainers Celcuity Inc. (NASDAQ: CELC) shares climbed 50.9% to close at $21.60 on Friday after the company announced a worldwide licensing agreement with Pfizer to develop and... 
Via Benzinga
Mid-Afternoon Market Update: Dow Surges Over 100 Points; Provention Bio Shares Plunge
Toward the end of trading Friday, the Dow traded up 0.42% to 33,645.90 while the NASDAQ rose 0.06% to 13,837.33. The S&P also rose, gaining 0.32% to 4,110.11. The U.S. has the... 
Via Benzinga
Topics Stocks
Exposures US Equities
Stocks Mixed at Midday, Still on Track for Solid Weekly Gains
The Dow is up roughly 75 points this afternoon. 
Via Talk Markets
Topics Stocks
Exposures US Equities
Mid-Day Market Update: WD-40 Drops After Weak Q2 Results; Celcuity Shares Jump
Midway through trading Friday, the Dow traded up 0.28% to 33,598.84 while the NASDAQ fell 0.16% to 13,806.77. The S&P also rose, gaining 0.13% to 4,102.64. The U.S. has the... 
Via Benzinga
Topics Stocks
Exposures US Equities
38 Stocks Moving In Friday's Mid-Day Session
Gainers Celcuity Inc. (NASDAQ: CELC) shares jumped 64.5% to $23.54 after the company announced a worldwide licensing agreement with Pfizer to develop and commercialize... 
Via Benzinga
Mid-Morning Market Update: Markets Open Higher; US Producer Prices Rise 1% In March
Following the market opening Friday, the Dow traded up 0.29% to 33,487.00 while the NASDAQ rose 0.01% to 13,748.50. The S&P also rose, gaining 0.21% to 4,097.50. The U.S. has... 
Via Benzinga
Topics Stocks
Exposures US Equities
Affimed Stock Jumps After Natural Killer Cells With AFM13 Show Clinical Responses, Minimal Toxicity
Affimed NV (NASDAQ: AFMD) has announced initial clinical data from an investigator-sponsored study evaluating cord blood-derived natural killer (cbNK) cells... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.